|
Targeted agents
|
VEGF-dependent angiogenesis inhibition
|
Cediranib (AZD2171)/US20070135462 (AstraZeneca)
|
Oral VEGFR-1,-2,-3 tyrosine kinase inhibitor
|
|
Nintedanib (BIBF1120)/US20140018405 (Boehringer Ingelheim)
|
Oral VEGFR, PDGFR, FGFR tyrosine kinase inhibitor
|
|
PARP inhibitors
|
Olaparib (AZD2281)/US2010098763 (AstraZeneca)
|
Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor
|
|
Rucaparib (CO-338)/US8765751 (Clovis Oncology)
|
Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor
|
|
Niraparib (MK-4827)/US20120035244 (Merck)
|
Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor
|
|
MEK inhibitors
|
Selumetinib (AZD6244)/US8193229 (Array BioPharma/AstraZeneca)
|
Oral inhibitor of MEK-1,-2
|
|
Binimetinib (MEK162)/US20130273061 (Array BioPharma/Novartis)
|
Oral inhibitor of MEK-1,-2
|
|
Cytotoxic agents
| |
Etirinotecan pegol (NKTR-102)/US20090074704 (Nektar)
|
Inhibits Topoisomerase I (IV)
|
| |
Paclitaxel poliglumex (CT2103)/US20070167349 (CTI BioPharma)
|
Mitotic inhibitor (IV)
|
|
Lurbinectedin (PM1183)/US20130266666 (PharmaMar)
|
Marine-derived DNA minor groove binder (IV)
|
|
Therapeutic vaccines
| |
Catumaxomab/US20120095192 (Trion Pharma)
|
Oral tri-functional antibody binds EpCAM, CD3, and Fc receptor
|
